US FDA’s Marks Issues ‘Provocative’ Call For Target Gene Therapy Profile That Includes Costs

 
• By Sarah Karlin-Smith
  
scientist holds 3d rendering of DNA molecule in hands.
The FDA's Peter Marks wants to lower the cost-effectiveness of gene therapy. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Cell & Gene Therapies

More from Advanced Technologies